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A B S T R A C T
Trimethyltin (TMT), an organotin with potent neurotoxic effects by selectively damaging to
hippocampus, is used as a tool for creating an experimental model of neurodegeneration. In the
present study, we investigated the protective effects of magnolol, a natural biphenolic compound, on
TMT-induced neurodegeneration and glial activation in vitro and in vivo. In HT22 murine neuroblastoma
cells, TMT induced necrotic/apoptotic cell death and oxidative stress, including intracellular reactive
oxygen species (ROS), protein carbonylation, induction of heme oxygenase-1 (HO-1), and activation of all
mitogen-activated protein kinases (MAPKs) family proteins. However, magnolol treatment signiﬁcantly
suppressed neuronal cell death by inhibiting TMT-mediated ROS generation and activation of JNK and
p38 MAPKs. In BV-2 microglial cells, magnolol efﬁciently attenuated TMT-induced microglial activation
via suppression of ROS generation and activation of JNK, p38 MAPKs, and nuclear factor-kB (NF-kB)
signaling. In an in vivo mouse study, TMT induced massive neuronal damage and enhanced oxidative
stress at day 2. We also observed a concomitant increase in glial cells and inducible nitric oxide synthase
(iNOS) expression on the same day. These features of TMT toxicity were reversed by treatment of
magnolol. We observed that p-JNK and p-p38 MAPK levels were increased in the mouse hippocampus at
day 1 after TMT treatment and that magnolol blocked TMT-induced JNK and p38 MAPK activation.
Magnolol administration prevented TMT-induced hippocampal neurodegeneration and glial activation,
possibly through the regulation of TMT-mediated ROS generation and MAPK activation.
ã 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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NeuroToxicology1. Introduction
The systemic administration of trimethyltin (TMT) to humans
and rodents induces substantial neuronal cell death, predomi-
nantly in the hippocampal neurons in the central nervous system
(CNS) resulting in clinical symptoms; cognitive impairment,
hyperactivity, aggressiveness, and seizure-like behaviors (Geloso
et al., 2011). Although the precise mechanisms by which TMT
targets hippocampal neurons have not been established, previous
research documented possible risk factors for neuronal cell death,
such as excitotoxicity (Gunasekar et al., 2001), intracellularAbbreviations: TMT, trimethyltin; ROS, reactive oxygen species; HO-1, heme
oxygenase; MAPKs, mitogen-activated protein kinases; NF-kB, nuclear factor-kB;
iNOS, inducible nitricoxide synthase.
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0161-813X/ã 2016 The Authors. Published by Elsevier Inc. This is an open access article uncalcium overload and mitochondrial damage (Noraberg et al.,
1998). Among these potential mechanisms, the majority of
research has focused on oxidative stress (Shin et al., 2005) and
neuroinﬂammation (McPherson et al., 2011) as major pathogenic
factors.
Oxidative stress is the result of an imbalance between the
production of free radicals, such as reactive oxygen species (ROS)
and reactive nitrogen species (RNS), and antioxidant activity
(Gandhi and Abramov, 2012). This imbalance is a common risk
factor for a range of neurodegenerative diseases since neurons are
highly vulnerable to oxidative stress, but free radicals can also
target a wide variety of cell types in CNS via disruption of signaling
processes and cell homeostasis (Gandhi and Abramov, 2012). The
by-products of oxygen consumption can further contribute to the
initiation of neuroinﬂammation (Harry and Kraft, 2008), which has
emerged as a key component of various neuropathologies. This
condition occurs as a localized response induced primarily by
activated microglia (Corvino et al., 2013). Microglia can be
activated by external stimuli such as neuronal damage (Lull and
Block, 2010) and lipopolysaccharide (LPS) (Harry and Kraft, 2008)der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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activation (Hsieh and Yang, 2013; Lull and Block, 2010). The
activated cells can then secrete a variety of bioactive factors,
including cytokines and free radicals, which stimulate a more
intensive inﬂammatory response and neuronal cell death (Corvino
et al., 2013, Harry and Kraft, 2008; Lull and Block, 2010).
Experimental observations supporting the role of oxidative
stress and neuroinﬂammation in TMT-induced neurodegeneration
have been reported. For example, ROS formation leading to the
dysregulation of glutathione homeostasis (Shin et al., 2005) and
increased 4-hydroxynonenal (4-HNE) formation (Huong et al.,
2011) provided the prominent evidence of oxidative stress-
induced neuron death following TMT exposure. However, a
neuroprotective effect was found with the administration of
ascorbic acid (Shin et al., 2005) or quercetin (Choi et al., 2012),
which were each able to counteract TMT-induced oxidative stress.
Evidence of the neuroinﬂammatory process during TMT-induced
neuronal cell death has also been reported. In TMT experimental
models, extensive glial activation occurs concomitantly with
hippocampal neuron death (Kim et al., 2014). Typically, microglial
activation is regarded as a primary source of inﬂammatory
regulators, such as inducible nitric oxide synthase (iNOS) and
cyclooxygenase 2 (COX-2), cytokines such as interleukin (IL)-1a, IL-
1b, and tumor necrosis factor a (TNF-a), that might contribute to
neuronal death (Corvino et al., 2013; Geloso et al., 2011; Kim et al.,
2014; Lull and Block, 2010). Although it is accepted that the
activation of microglia in acute TMT toxicity may be associated
with neuronal repair (McPherson et al., 2011), previous studies
suggested that suppression of the inﬂammatory process using
neutralizing antibodies against TNF-a (Harry et al., 2002) and
indomethacin (Huong et al., 2011) signiﬁcantly protected neuron
cell death in TMT-treated animal models. From these backgrounds,
it seems mandatory to ﬁnd a multi-potent agent possessing
antioxidant and anti-inﬂammatory properties for the protection of
TMT-induced neurotoxicity.
Magnolol, which is extracted from Magnolia ofﬁcinalis, is a
natural, biphenolic compound. The properties of magnolol have
been broadly investigated and include anti-oxidant (Chuang et al.,
2013; Muroyama et al., 2012), anti-inﬂammatory (Lee et al., 2005),
and anti-tumorigenic activities (Seo et al., 2011). Recently,
magnolol was suggested to have beneﬁcial effects in the CNS
with several studies reporting that magnolol prevented dopami-
nergic neuronal loss and glial activation in the Parkinson’s disease
models involving 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(Chuang et al., 2013; Muroyama et al., 2012) or 6-hydroxydop-
amine (Chen et al., 2011). Moreover, neuronal excitotoxicity and
inﬂammatory responses in microglial cells were also improved by
magnolol administration (Chuang et al., 2013). The actual
molecular mechanisms or signaling cascades through which
magnolol induces CNS protection have not yet been fully clariﬁed;
however, some evidence suggest the involvement in a ROS
scavenging effect and the regulation of signaling pathways, such
as MAPKs and NF-kB signaling, also may be involved (Chen et al.,
2014; Chuang et al., 2013; Lee et al., 2005).
In the present study, therapeutic strategies for using magnolol in
TMT-induced neuronal cell death and glial activation were
evaluated both in vitro and in vivo. In cell culture experiments,
HT22 neuroblastoma cells and BV-2 microglial cells, which both
originated from mice, were used to investigate the protective effects
of magnolol on TMT-induced neuronal cell death and microglial
activation. Further, beneﬁcial effects of magnolol were demon-
strated in TMT-injected mouse. This neurodegenerative model was
also used to provide the roles and mechanisms of MAPK signaling
pathways in this response.2. Materials and methods
2.1. Reagents
Dulbecco’s modiﬁed Eagle’s medium (DMEM), phosphate-
buffered saline (PBS), Hank’s balanced salt solution (HBSS), fetal
bovine serum (FBS), and antibiotic-antimycotic solution were
purchased from Gibco (Grand Island, NY, USA). TMT, 2,7-dichloro-
ﬂuorescein diacetate (DCFH-DA), dimethyl sulfoxide (DMSO),
bovine serum albumin, sodium orthovanadate, sodium ﬂuoride,
heparin, Tween-20, Hoechst 33258, SB203580, and SP600125 were
purchased from Sigma–Aldrich (St. Louis, MO, USA). U0126 was
purchased from Calbiochem (San Diego, CA). Rabbit antibodies
against p-JNK, p-p38, p-ERK, p38, p-IkBa, IkBa, bcl-2, bax, cleaved
caspase-3, ionized calcium binding adaptor molecule 1 (Iba1), and
glial ﬁbrillary acidic protein (GFAP) were purchased from Cell
Signaling Technologies, Inc. (Beverly, MA, USA). Rabbit anti-JNK,
ERK, and NF-kB p65, and mouse anti-NeuN antibodies were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Mouse anti-iNOS was purchased from BD Biosciences (Franklin
Lakes, NJ, USA). Mouse anti-actin was purchased from EMD
Millipore (Billerica, MA, USA). The goat anti-mouse and anti-rabbit
IgG (HRP-conjugated) secondary antibodies and heme oxygenase 1
(HO-1) primary antibody were from Enzo Life Science (Farm-
ingdale, NY, USA). All other chemicals were purchased from Sigma–
Aldrich.
2.2. Cell culture and treatment
Cells were grown at 36C in a 5% CO2 incubator in high glucose
DMEM supplemented with 10% (v/v) heat-inactivated FBS, 1x
antibiotic-antimycotic solution (consisting of 100 units/ml peni-
cillin, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B),
2 mM L-glutamine, and 1 mM pyruvate at pH 7.4. At 80%
conﬂuence, cells were harvested for subculture. Freshly seeded
cells on a culture plate were incubated overnight in a culture
medium containing 10% heat-inactivated FBS and antibiotic-
antimycotic solution, and then the culture medium was replaced
with low-glucose DMEM with 1% FBS for 6 h (for HT22 cells) or 4 h
(for BV-2 cells) prior to experimental treatment. Pretreatments of
magnolol, vehicle (0.1% DMSO), and each inhibitor, including
SB203580 (p38 MAPK inhibitor), SP600125 (JNK MAPK inhibitor),
and U0126 (MEK inhibitor), were made 1 h before the treatment of
TMT and dissolved in sterile 0.9% saline. For ROS generation and
Western blot, culture medium was changed to low glucose DMEM
without FBS and antibiotic-antimycotic solution.
2.3. Cell death determination
To quantify the percentage of cell death, propidium iodide (PI)
ﬂuorescence was measured using a microplate reader (Nieminen
et al., 1992) with some modiﬁcations. In a 96-well tissue culture
plate, 1.2  103 HT22 cells were seeded per well. Cells were
pretreated with magnolol and inhibitors for 1 h before TMT
administration and incubated for an additional 24 h. PI (ﬁnal
concentration, 20 mg/ml) was added to the treated wells at 36C in
5% CO2 for 30 min. The initial ﬂuorescence from the dead cells was
measured by a microplate reader with an excitation at 530 nm and
an emission at 630 nm. Next, 2% sodium dodecyl sulfate was added
to each well to permeabilize all cells and bind all nuclei with PI.
Then, PI ﬂuorescence was re-measured to assess the value of total
cells. The percentage of cell death for each sample was calculated
as (ﬂuorescence of treated cells/ﬂuorescence of lysed cells)100.
To measure the number of apoptotic cells, treated cells plated on a
96-well culture plate were incubated with Hoechst 33258 (1 mg/
ml) dissolved in PBS for 20 min and then examined using a
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were captured and examined. The percentage of apoptotic cells
were calculated as (number of nuclei with apoptotic morphology/
total number of nuclei)  100.
2.4. Measurement of ROS
Intracellular ROS generation was measured using DCFH-DA
assays (Kim and Kim, 2015). In 60 mm2 tissue culture dishes (BD
Biosciences, Franklin Lakes, NJ, USA), treated cells at a density of
1 106 cells/ml were washed twice with pre-warmed HBSS. Next,
the cells were incubated with 15 mM DCFH-DA at 36C in a CO2
incubator for 30 min. The cells were again washed twice. A Canto
Flow Cytometer (BD Biosciences, CA, USA) was used to quantify the
ﬂuorescent cells using excitation at 488 nm and emission at
510 nm. For statistical comparisons, the control value was set at
100%.
2.5. Western blot analysis
Tissue samples or treated cells were lysed with radioimmuno-
precipitation assay buffer (Elpis Biotech, Daejeon, Korea) supple-
mented with protease and phosphatase inhibitor cocktails (Roche
Diagnostics, Rotkreuz, Switzerland) and then separated by
centrifugation at 14,000  g for 20 min at 4C. The supernatant
was collected, and Bradford assays were used to measure the
protein concentrations. Equal protein amounts (20 mg) were
separated by 10% sodium dodecyl sulfate polyacrylamide gel
electrophoresis and then transferred onto a 0.45 mm pore size
nitrocellulose membrane (Bio-Rad Laboratories, Hercules, CA,
USA) for 1 h at 100 V. After 1 h of blocking in 5% skim milk dissolved
in Tris-buffered saline (TBST), pH 7.4, containing 1% Tween-20 for
1 h at room temperature, the membranes were incubated
overnight at 4C with primary antibodies against p-p38
(1:1000), p-JNK (1:1000), p-ERK (1:2000), p-IkBa (1:2000), IkBa
(1:2000), p38 (1:2000), JNK (1:2000), ERK (1:2000), iNOS
(1:1000), GFAP (1:3000), Iba1(1:2000), HO-1 (1:2000), NeuN
(1:2000), cleaved caspase-3 (1:1000), bcl-2 (1:1000), bax (1:1000),
or actin (1:2000). After washing with TBST three times for 10 min
each, membrane was incubated with goat anti-rabbit IgG-
horseradish peroxidase (HRP) or anti-mouse IgG-HRP for 1 h,
and then again rinsed three times with TBST. The blots were
immunolabeled with enhanced chemiluminescence HRP substrate
(Thermo Fisher Scientiﬁc Inc, Rockford, IL, USA) and Chemi-
DocTMXRS plus (Bio-Rad laboratories, Hercules, CA, USA) was used
to analyze the immunoblot. Actin was used as a total protein
loading control.
2.6. Protein carbonylation
To quantify the amount of protein carbonylation, experiments
were performed using the OxyBlot Protein Oxidation Detection Kit
(EMD Millipore Corporation, Billerica, MA, USA) in accordance with
the manufacturer’s instructions. In brief, derivatization of the
carbonyl groups in each sample was accomplished with 2,4-
dinitrophenylhydrazine (DNPH) and then proteins were separated
by electrophoresis. After transferring to a nitrocellulose mem-
brane, DNPH expression was detected using an antibody speciﬁc to
DNPH (1:200).
2.7. Measurement of NO and TNF-a release into the culture medium
BV-2 cells (2.5 104) seeded in a 24-well tissue culture plate
(Thermo Fisher Scientiﬁc Inc.) were treated with TMT in low-
glucose DMEM containing 1% (v/v) FBS for 24 h. Then, the medium
was removed and separated by centrifugation at 500  g for 5 minat 4 C. The supernatant fraction was collected for the measure-
ment of NO and TNF-a. For the NO measurements, a general
protocol was followed as described previously (Jenkins and Barone,
2004). Brieﬂy, 90 mL of each sample and 10 mL of Griess reagent
(containing 0.1% N-[1-naphthyl] ethylenediamine dihydrochloride
in 5% H3PO4 with 1% sulfanilic acid) was placed in a 96-well tissue
culture plate (BD Biosciences). For the standard values, different
concentrations of sodium nitrite solution and Griess reagent were
placed into the plate. The plate was then gently shaken for 30 min.
Absorbance was read on a microplate reader set at 540 nm. The
nitrite concentration of each sample was calculated from the
standard curve. A TNF-a enzyme-linked immunosorbent assay
(ELISA) kit (Abcam, Cambridge, UK) was used to measure the
amount of released TNF-a. Each dilution of the standard and each
sample were added to the plate, and subsequent experiments were
performed according to the manufacturer’s protocol. The TNF-a
measurements were collected using a microplate reader set at
450 nm. The concentration of each sample was calculated from the
standard curve.
2.8. Animals
Five-week-old male ICR mice were obtained from Samtako
(Osan, Korea). Mice were maintained for seven days individually in
a cage with a 12-hour light/dark cycle and free to access water and
food. Procedures for animal care and handling were performed in
accordance with the NIH guide for the Care and Use of Laboratory
Animals. The Seoul National University Institutional Animal Care
and Use Committee (SNU-141208-3) approved the experimental
procedures and protocols conducted during this study.
2.9. Drug administration and tissue preparation
Trimethyltin chloride (Sigma–Aldrich, St. Louis, MO, USA)
dissolved in sterile 0.9% saline, magnolol (Wako, Osaka, Japan)
dissolved in 10% DMSO, 10% cremophor, PBS, and vehicle were
provided immediately before administration. After seven days of
adaptation, animals were randomly divided into four different
groups. Mice received intraperitoneal (i.p.) injections of 25 mg/kg
magnolol or vehicle on day 1, 1 h prior to and 2 h after TMT (2.6 mg/
kg, i.p.) or 0.9% saline administration. Animals were scariﬁed 1 or
2 days after TMT administration. Mice belonging to the day 1 group
were sacriﬁced 2 h after the ﬁnal injection of magnolol to
maximize its effect. All efforts were made to minimize animal
suffering and the number of mice used in the in vivo experiments.
For histochemical analysis, animals were anesthetized with
Avertin (250 mg/kg, i.p.) and perfused via the heart with freshly
made PBS containing 2 mM orthovanadate, 20 mM sodium
ﬂuoride, 12 units/ml heparin, and a 4% paraformaldehyde solution,
pH 7.4. The mouse brains were removed and stored in 30% sucrose
dissolved in PBS following overnight post-ﬁxation in a 4%
paraformaldehyde solution. Coronal 30 mm-thick brain sections
were used for the appropriate experiments.
2.10. Hippocampal neuronal damage
Fluoro-Jade B (FJB; Millipore, Billerica, MA, USA), possessing a
high preference for degenerating neurons, was used to determine
the extent of cell death induced by TMT in the hippocampus.
Brieﬂy, brain sections were mounted on gelatin-coated glass slides
and immersed in a 0.06% potassium permanganate and 0.0004%
FJB solution. After washing three times, the sections were dried in
the dark. Stained sections were examined using a ﬂuorescence
microscope (Axioskop 40; Carl Zeiss, Jena, Germany). The counting
of FJB-positive cells in the hippocampus was performed as
previously described (Kim et al., 2014). The fraction of cells
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ImageJ software (NIH, Bethesda, MD, USA). Obtained images were
converted into 8-bit grayscale, the colors were inverted, and the
threshold value of the image was adjusted until none of the FJB
negative cells were detectable. The same threshold was then
applied to all images. For each mouse, sections of the hippocampus
taken every 180 mm were examined for counting. The total number
of FJB positive cells was divided into the number of tissues
examined in order to obtain the average intensity.
2.11. Tissue sampling for biochemical assays and Western blots
After 1 and 2 days of TMT administration, animals were
decapitated and the hippocampus was isolated. Brieﬂy, a sagittal
incision was made to separate the two hemispheres and the
cortex, and meningeal tissue surrounding the hippocampus were
removed using forceps. The resulting tissue samples were
immediately immersed in cold lysis buffer (Elpis Biotech,
Daejeon, Korea) containing protease and phosphatase inhibitor
cocktails and the samples were sonicated for 10 cycles of 2 sec
pulses with 30% amplitude on ice. The protein carbonylation and
Western blot analysis procedures were performed as described
above.
2.12. Statistical analyses
The data are presented as the mean  SEM. GraphPad Prism
software version 5.0 (San Diego, CA, USA) for Windows was used to
analyze the data. One-way analysis of variance test with Tukey’s
multiple comparisons was used to examine the differences between
groups. A p value below 0.05 was considered to be statistically
signiﬁcant.
3. Results
3.1. Magnolol was protective against TMT-induced HT22 cell death
The cytotoxicity of TMT in HT22 cells was initially examined.
The cells were incubated with TMT concentrations from 5 mM to
20 mM for 24 h, and then the PI assay was performed to assess the
ratio of cell death (Fig. 1a). TMT cytotoxicity increased in a dose-
dependent manner with signiﬁcant increases observed from
10 mM to 20 mM (10 mM, 20.5  4.6%; 15 mM, 35.4  3.9%; andC
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Fig. 1. Magnolol protected against TMT-induced HT22 neuronal cell death. (a) Cells we
pretreated with 5 mM magnolol or vehicle (0.1% DMSO) for 1 h and then treated with 15
percentage of dead cells. Data are presented as the mean  SEM (n = 5). *p < 0.05 compare
control, M: magnolol, T: TMT, T + M: TMT + magnolol.20 mM, 48.9  3.5%). Based on these results, 15 mM TMT was
selected for use in subsequent experiments. To evaluate the effect
of magnolol on TMT-induced cell death, HT22 cells were treated
with magnolol (5 mM) or vehicle (0.1% DMSO) for 1 h prior to TMT
treatment. With these conditions, magnolol caused an approxi-
mately 65% reduction in TMT-induced cell death (TMT, 38.3  1.8%;
TMT + magnolol, 13.5  2.6%; Fig. 1b).
To evaluate the effects of magnolol on TMT-induced HT22 cell
apoptosis, cells were treated as described above and at 24 h the
numbers of fragmented and intact nuclei were counted following
Hoechst 33258 staining. A large number of cells with DNA
fragmentation were observed in the TMT treatment group, while
magnolol pretreatment was shown to effectively reverse TMT-
induced cell death (Fig. 2a). Other parameters related to apoptosis
were also examined by Western blot. The results clearly
demonstrated a decrease in bcl-2 expression. In contrast, the
expression of bax and cleaved caspase-3 was increased following
TMT treatment (Fig. 2b). These changes induced by TMT were
reversed by magnolol pretreatment (Fig. 2b). Together, these data
indicate that apoptotic cell death induced by TMT was efﬁciently
prevented with magnolol pretreatment.
3.2. Magnolol reduced TMT-induced HT22 cell oxidative stress
The induction of oxidative stress by TMT has been previously
reported (Huong et al., 2011; Qing et al., 2013). To test the
generation of ROS induced by TMT in HT22 cells and effects of
magnolol on this induction, ROS production was measured by a
DCFH-DA assay performed at each indicated time point. The
results showed signiﬁcantly elevated DCF ﬂuorescence from 1 h to
9 h after initial TMT exposure (Fig. 3a). However, a gradual
reduction in TMT-mediated ROS generation by magnolol was
apparent at 1 h after TMT treatment (Fig. 3b). We further
examined alternations in protein carbonylation and HO-1 expres-
sion at 24 h after TMT treatment. A large quantity of protein
carbonylation was detected by TMT, and magnolol suppressed
this elevation (Fig. 4a). Induction of HO-1 has been frequently
reported as an adaptive response to oxidative stress (Kamalvand
et al., 2003). In this experiment, we observed an increased level of
HO-1 induced by TMT (Fig. 4b). Moreover, treatment with
magnolol attenuated HO-1 expression (Fig. 4b). These results
show that magnolol was effective in reducing these parameters in
HT22 cells.0
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induced HT22 cell death
Activation of MAPKs has been documented to play a crucial role
in TMT toxicity (Jenkins and Barone, 2004; Qing et al., 2013). In the
present study, we examined MAPK expression levels after TMT
exposure in a time-dependent manner. As shown in Fig. 5a, all
MAPK family proteins, including JNK, ERK, and p38, were
phosphorylated by TMT. In particular, p-JNK and p-p38 were
remarkably enhanced at 1 h and 2 h and declined thereafter. The
level of p-ERK was also increased from 1 h to 6 h and was then
reduced at 8 h post-treatment. To further evaluate the role of
MAPKs on TMT-induced neuronal cell death, the activation of each
MAPK family member was suppressed by pretreatment of cells
with the inhibitors SP600125 (JNK inhibitor), SB203580
(p38 inhibitor), or U0126 (MEK inhibitor). The PI assay was
performed after 24 h of TMT treatment in order to determine the
proportion of dead cells. Interestingly, a signiﬁcant suppression of
TMT-induced neuronal cell death was observed by treatment of
SB203580 as compared to the other inhibitors (Fig. 5b). This ﬁnding
emphasizes the importance of p38 MAPK activation in TMT-
induced HT22 neuronal cell death.0
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An additional investigationwas performed to evaluate the effects
of magnolol on TMT-induced MAPK activities. After 1 h of TMT
treatment, the magnolol-induced down-regulation of TMT-induced
p-JNK and p-p38 MAPK formation was detected (Fig. 6). However,
magnolol did not inﬂuence TMT-mediated p-ERK expression.
3.5. Magnolol suppressed TMT-induced microglial activation via
inhibition of ROS generation/MAPKs and NF-kB activation in BV-
2 microglial cells
We recently reported that TMT induces microglial activation in
BV-2 cells (Kim and Kim, 2015). To determine if magnolol
inﬂuences TMT-induced microglial activation, alternations in
these parameters were investigated following magnolol treatment.
To avoid cytotoxic effects, BV-2 cells were treated with 3 mM TMT.
As shown in Fig. 7, TMT treatment induced signiﬁcant increases in
DCF ﬂuorescence and activation of p-JNK and p-38 MAPK at 6 h;
however, these results were inhibited by magnolol pretreatment
(Fig. 7a, b and c). Magnolol was also effective at suppressing TMT-0
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Fig. 6. Magnolol suppressed TMT-induced p-JNK and p-p38 expression in HT22 cells. Treated cells were collected following 1 h of TMT treatment and subjected to Western
blot analysis. The bar graph represents the band intensity of p-JNK, p-ERK, and p-p38 protein forms normalized to the total expression of each protein. Data are presented as
the mean  SEM (n = 3–6). *p < 0.05 compared with the control group, #p < 0.05 compared with the TMT treatment alone. C: control, M: magnolol, T: TMT, T + M:
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IkBa and degradation of IkBa at 12 h (Fig. 7d).
3.6. Magnolol suppressed TMT-induced BV-2 microglial cell release of
NO and TNF-a
iNOS expression determined by Western blot analysis was
signiﬁcantly increased by TMT treatment, but magnolol inhibited
this elevation at 12 h (Fig. 8a). Secretion of the soluble factors NO
and TNF-a (Fig. 8b,c) after exposure to TMT for 24 h was also
notably decreased by magnolol pretreatment. Therefore, magnolol
treatment was effective at preventing TMT-induced BV-2 cell
microglial activation via inhibition of ROS generation, activation of
MAPKs and NF-kB, and release of NO and TNF-a.
3.7. Magnolol protected against TMT-induced neuronal cell death in
mouse hippocampus
Following our in vitro observations, magnolol protection against
TMT-induced cell death and microglial activation, the effect of
magnolol on TMT neurotoxicity was evaluated in an in vivo study.
To ﬁrst establish the protective effects of magnolol against TMT-
induced hippocampal neuron cell death, hippocampus tissue
sections obtained at 2 days after TMT exposure were stained with
FJB. As shown in Fig. 9a, the number of degenerating neurons in the
dentate gyrus following TMT administration was effectively
blocked by treatment with magnolol. Magnolol neuroprotection
against TMT toxicity were also conﬁrmed by Western blot analysis
of NeuN and cleaved caspase-3 expression (Fig. 9b). TMT induced a
massive decrease in NeuN expression and an elevation in cleaved
caspase-3 compared to the control animals. These changes were
markedly prevented by magnolol pretreatment. These results
reveal that magnolol protects against TMT-induced neuronal death
in the mouse hippocampus.
3.8. Magnolol reduced TMT-mediated oxidative stress in mouse
hippocampus
To evalaute the effects of magnolol on TMT-mediated oxidative
stress in mice, protein carbonylation and HO-1 expression at
2 days of TMT administration were exvaluated by Western blot
analysis (Fig. 10). Protein carbonylation was prominently elevated
by TMT alone (Fig. 10a). HO-1 expression was also increased
by TMT (Fig. 10b). However, magnolol treatment diminished0
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3.9. Magnolol decreased TMT-induced glial activation and iNOS
expression in mouse hippocampus
Potential alternations in TMT-induced glial activation were
also evaluated. Activation of glial cells is one of the more
prominent pathologic features of TMT model systems along with
granule cell death (McPherson et al., 2011; Kim et al., 2014). On
day 2 of TMT treatment, glial cell expression was analyzed by
Western blot analysis. TMT upregulated and magnolol suppressed
the expression of GFAP, an astrocyte marker, and Iba1, a marker of
microglia, resulting in TMT upregulation and magnolol suppres-
sion of glial activation (Fig. 11a and b). Along with glial activation,
iNOS expression was also increased by TMT, and magnolol
prevented TMT-induced iNOS expression (Fig. 11c). Therefore,
magnolol not only prevented neuronal cell death but was also
effective in attenuating TMT-induced glial activation and iNOS
expression.
3.10. Magnolol decreased TMT-induced activation of JNK and p38 in
the mouse hippocampus
In the present study, TMT treatment activated MAPKs, and
p38 activation was found to be crucial for TMT-induced
neurotoxicity in HT22 cells and p38 and JNK activation for
microglial activation in BV-2 cells (Fig. 5; Fig. 7b and c). Evaluation
of the relevance of our in vitro data in an in vivo model system
conﬁrmed the presence of altered MAPK activity in the hippocam-
pus at 1 day post-TMT treatment. p-JNK and p-p38 induction in the
TMT treatment group was clearly shown by Western blot analysis,
but there was no signiﬁcant change in p-ERK following TMT
treatment (Fig. 12). With magnolol treatment, TMT-induced p-JNK
and p-p38 was again inhibited in the mouse hippocampus as was
observed in the cell culture model system (Fig. 6; Fig. 7b and c).
Thus TMT increased p-JNK and p-p38 in the mouse hippocampus,
and magnolol treatment inhibited the TMT-induced upregulation
of this protein phosphorylation.
4. Discussion
The present study investigated the effects of magnolol
treatment on TMT toxicity both in vitro and in vivo. The results(c)
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HT22 cell necrotic/apoptotic cell death and BV-2 cell microglial
activation. Furthermore, magnolol protected against neuronal
death coincident with the inhibition of glial activation in the
hippocampus of TMT-injected mice. Among the regulatory effects
exerted by magnolol, prevention of oxidative stress and MAPK
activation showed that these changes are essential to the
progression of TMT-induced neurodegeneration.
Excessive ROS formation, caused by imbalanced oxygen
consumption, has long been implicated as the major factor causing
neuronal damage (Gandhi and Abramov, 2012; Thannickal and
Fanburg, 2000) since they are highly reactive and able to damage
DNA, proteins, and lipids (Thannickal and Fanburg, 2000).
Accumulating evidence indicates that oxidative stress is not only
the by-product of cellular metabolism but also contributes to the
activation of cell signaling pathways and transcriptional regulatory
factors involved in the cellular functions mediated by NF-kB and
MAPK family activation (Gao et al., 2013; Lull and Block, 2010). ROS
generation is regarded as a pathogenic factor during TMT toxicity
and ROS formation following TMT exposure caused the death of
primary neurons (Gunasekar et al., 2001) and several different
neuroblastoma cell lines (Jenkins and Barone, 2004; Qing et al.,
2013; Zhang et al., 2006). It is also reported to trigger depletion of
glutathione, lipid peroxidation and protein oxidation (Shin et al.,
2015) in the murine hippocampus. Following reports on earlier
studies, we ﬁrst conﬁrmed the occurrence of oxidative stress with
TMT in our experimental conditions by examining severalbiomarkers for oxidative stress. From these studies, generation
of intracellular ROS at an early time point and an intensive increase
in protein carbonylation at a later time point following TMT
treatment were both detected in HT22 cells. Furthermore,
increased HO-1 expression was detected in these cells. HO-1, an
inducible isoform of HO, is used as a marker of oxidative stress that
becomes highly expressed in the presence of free radicals and also
induces anti-inﬂammatory and anti-oxidative activities (Kamal-
vand et al., 2003). In the hippocampus of TMT-treated mice,
protein carbonylation and HO-1 expression were signiﬁcantly
increased, which was consistent with the results in HT22 cells. This
oxidative burden provoked neuronal cell loss as shown by Western
blot analysis (NeuN and cleaved caspase-3) and histochemical
analysis of FJB. These data conﬁrmed the selective neuronal cell
death in the mouse hippocampus induced by TMT as has been
previously reported (Harry and Bruccoleri, 2003; Huong et al.,
2011), but also strongly suggested the involvement of oxidative
stress in this neuropathology.
Neuroinﬂammation has a close relationship with oxidative
stress in various neuropathologies. It is comprised of glial
activation and increased production of cytokines in a response
to CNS stimuli. External stimuli or intracellular ROS generation can
directly activate microglia, which both mediates the response to
inﬂammatory factors and triggers further inﬂammatory responses
and the generation of free radicals (Corvino et al., 2013; Harry and
Kraft, 2008). In TMT model systems, glial activation along with
enhanced production of the pro-inﬂammatory factors IL-1b, IL-12,
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Fig. 10. Magnolol suppressed TMT-induced oxidative stress in the hippocampus. Tissues obtained from mice 2 days after TMT treatment were subjected to Western blot
analysis of (a) protein carbonylation, and (b) HO-1 expression. The bar graphs represent the band intensity of protein carbonyls and HO-1 normalized to actin. Data are
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et al., 2005). Microglial activation has been suggested as a
dominant feature for inﬂammatory processes since potentiated
neuronal cell death and elevated levels of the cytokines IL-1b, IL-6,
and TNF-a were detected from a co-culture of primary neurons
with microglia (Eskes et al., 2003), and elevation of pro-
inﬂammatory cytokine mRNA levels belonging to the M1 stage
(Kim et al., 2014) were also found under TMT exposure.
Although there is existing evidence that activated microglia
contribute to cell proliferation and differentiation (Tambuyzer0
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Fig. 11. Magnolol suppressed TMT-induced glial activation and iNOS in the mouse hipp
Western blot analysis. The bar graph represents the band intensity of (a) GFAP, (b) Iba
*p < 0.05 compared with the control group, #p < 0.05 compared with the value followiet al., 2009), it has been predominantly suggested to be
deleterious to neuronal survival during TMT toxicity. Typically,
enhanced TNF-a production is apparent with microglial
activation (Eskes et al., 2003; Kim et al., 2014) and the severity
of neuronal death following TMT intoxication improves with the
administration of a neutralizing antibody to TNF-a (Harry et al.,
2002), resulting in the proposition that TNF-a has a critical role
during TMT-mediated neuronal death. Previously we have
shown that in BV-2 microglial cells, TMT directly activates
microglia via NADPH oxidase and MAPKs (Kim and Kim, 2015).0
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study showed that the TMT-induced activation of glial cells
coincided with neuronal cell death in the hippocampus. We also
observed a signiﬁcant increase in iNOS expression by day 2 after
TMT administration, and an extensive amount of iNOS in the
hippocampus, most typically focused within the damaged
region, was seen upon immunohistochemical examination (data
not shown). In general, induction of iNOS is tightly linked with
inﬂammatory processes such that it is activated by pro-
inﬂammatory cytokines or foreign pathogens to increase NO
generation for the defense of glial cells (Harry and Kraft, 2008;
Lull and Block, 2010). A by-product of iNOS activation, NO is
then able to mediate either excessive oxidative stress and
damage or additional inﬂammatory responses (Harry and Kraft,
2008; Latini et al., 2010; Lull and Block, 2010). A recent study
(Yang et al., 2012) reported the elevation of pro-inﬂammatory
mediators COX-2 and iNOS in the hippocampus of the TMT-
injured brain 4 days after TMT exposure. This result is in
agreement with the present data; however, other reports
contradicted our results and showed no alteration in iNOS
mRNA in the mouse hippocampus until after 3 days of TMT
exposure (Bruccoleri and Harry, 2000).
A number of researchers have been working to discover new
drug candidates for use with the neurodegenerative diseases
associated with limbic system dysfunction. With TMT-mediated
neuronal damage, repeated administration of ascorbic acid to rats
for 3 weeks partially protected against TMT-induced neuronal
damage and cognitive impairment (Shin et al., 2005). A pyridoin-
dole antioxidant also prevented TMT-induced rat pyramidal cell
death in CA1 area (Gasparova et al., 2014). Flavonoid dietary
supplements such as Ginkgo biloba extract (Kaur et al., 2013),
quercetin (Choi et al., 2012), and rutin (Koda et al., 2009) have also
been investigated as potential measures to counteract the neuronal
damage induced by TMT. Rutin supplementation (Koda et al., 2009)
was also reported to suppress microglia activation and cytokine
production in TMT-treated rats. One anti-inﬂammatory strategy
was the administration of TNF-a neutralizing antibodies, which
provided remarkable neuroprotection in mice (Harry et al., 2002).
In addition, indomethacin, a COX-2 inhibitor, provided partial
neuroprotection in TMT-treated mice (Huong et al., 2011). Even
though these pharmacological agents are reported to displaypotential therapeutic beneﬁts such as scavenging free radicals or
suppressing glial activation, a variety of different pathogenic
mechanisms can occur simultaneously during neurodegeneration,
necessitating the use of a multi-functional therapeutic agent to
provide optimal protection. Thus, the rationale for the investiga-
tion of therapies that possess both antioxidant and anti-
inﬂammatory properties was suggested to counter TMT toxicity,
and we chose to evaluate magnolol as a tool for improving the
neuropathogenic features.
Magnolol is a natural, biphenolic compound that is able to
cross the blood-brain barrier (Muroyama et al., 2012). The
diverse biological activities of magnolol have been extensively
documented and include anti-tumorigenic (Seo et al., 2011) and
anti-inﬂammatory (Chuang et al., 2013; Lee et al., 2005)
activities. In addition, regulation of oxidative stress has been
frequently reported in vivo (Chen et al., 2014; Muroyama et al.,
2012) and in vitro (Chuang et al., 2013). Current research has
focused on the beneﬁts of magnolol in treating neuropatho-
genesis. For instance, magnolol is reported to exert anti-
inﬂammatory effects through the regulation of p38 MAPK, CHOP,
and nitrotyrosine production in an ischemic injury model (Chen
et al., 2014) and attenuation of dopaminergic cell loss (Chen et al.,
2011) and glial activation (Muroyama et al., 2012) by anti-
oxidative mechanisms in Parkinson’s disease models. Based on
current evidence, the effects of magnolol on TMT toxicity were
evaluated in the present study. The use of magnolol as a
therapeutic antioxidant agent ameliorated TMT-mediated oxida-
tive stress, thereby protecting against neuronal death in the
mouse hippocampus and HT22 cell necrotic/apoptotic cell death.
Certain anti-inﬂammatory properties of magnolol were also
revealed. In BV-2 cells, magnolol regulated microglial activation
and production of inﬂammatory factors (iNOS, NO, and TNF-a)
through the inhibition of NF-kB activation. In mice, activation of
astrocytes and microglia following TMT administration was
prevented by treatment with magnolol at day 2. Effective
suppression of iNOS protein was shown by magnolol on the
same day. These results were similar to those from previous
investigations that highlighted anti-oxidative and anti-inﬂamma-
tory mechanisms against external stimuli such as LPS (Chuang
et al., 2013; Zhou et al., 2008), interferon gamma (IFN-g) (Chuang
et al., 2013), and foreign pathogens (Lee et al., 2005).
184 D.J. Kim, Y.S. Kim / NeuroToxicology 53 (2016) 173–185The activation of MAPKs is one important consequence of
oxidative stress. Once the MAPK signaling pathway is initiated, it
can regulate multiple cellular functions, such as cell proliferation,
differentiation, and death. While inﬂammatory responses occur
in a variety of circumstances, MAPK signaling cascades can be
crucial contributors. For example, LPS (Chuang et al., 2013) and
rotenone (Gao et al., 2013) activate microglia via p38 activation,
and amyloid beta-mediated microglial activation requires JNK
and p38 activation (Park et al., 2012). The role of MAPK activation
in TMT toxicity has been emphasized, including JNK and ERK in
SH-SY5Y cell death (Qing et al., 2013), p38 in PC12 cell death
(Jenkins and Barone, 2004) and JNK and p38 in BV-2 cell
microglial activation (Kim and Kim, 2015). Despite, most of these
reports were conducted using cell culture system. A limited
number of studies have conﬁrmed the role of MAPK modulation
using TMT-injured mice; activation of JNK in CA1 pyramidal and
dentate gyrus cell layers from 16 h to 24 h after TMT treatment
(Ogita et al., 2004), suggesting the possible involvement of JNK
activation in TMT-induced neuronal cell death in the brain. Also,
blocking JNK with SP600125 partially protected against TMT-
mediated neuronal death in mouse primary cortical neurons
(Shuto et al., 2009). From this background, our efforts were made
to evaluate the role of MAPK signaling pathway in TMT toxicity
and its modulation by magnolol as a therapeutic agent in vitro and
in vivo.
In the present study, we found that phosphorylation of all of
the MAPK family proteins following activation by TMT treatment,
and inhibition of p-p38 by SB203580, a p38 MAPK inhibitor,
signiﬁcantly prevented TMT-induced neuronal HT22 cell death.
Again, magnolol treatment reduced p-JNK and p-p38 levels in the
same experimental condition. Furthermore, p-JNK and p-
p38 were both associated with TMT-induced microglial activation
in BV-2 cells, and magnolol achieved a suppressive effect on both
microglial activation and the production of inﬂammatory bioac-
tive factors. Based on these ﬁndings, MAPK protein family
activation may be essential for TMT-induced neuronal cell death
and microglial activation, and magnolol has the capacity to
protect against both of these responses. We further demonstrated
that TMT can activate any MAPK family member in the
hippocampus under our current experimental conditions, and
that magnolol is capable of regulating this TMT-induced MAPK
activation. As a result, we observed the activation of p38 in
addition to JNK activation in the hippocampus at day 1 after TMT
administration. The inhibitory effects on p-p38 and p-JNK were
also mediated by magnolol when given on the same day of the
experiment. These ﬁndings from in vitro and in vivo experiments
suggest a correlation between MAPK signaling activation during
TMT-induced neurodegeneration and its modulation by magnolol.
In particular, our in vivo data suggest a possible role for p38 and
JNK activation in the TMT-induced neurodegeneration and glial
activation in the hippocampus. Additional investigations are
needed to deﬁne which type of cells in brain is the main source
for MAPK activation following TMT treatment and the speciﬁc
roles for MAPK activation during TMT-induced neuronal damage in
vivo.
5. Conclusions
In the present study, we demonstrated that oxidative stress and
MAPK signaling components are induced by TMT toxicity.
Magnolol regulates TMT-mediated ROS generation and MAPK
activation. Taken together, magnolol possesses strong potential as
a therapeutic for combating neurodegenerative diseases associat-
ed with oxidative burden and neuroinﬂammation.Conﬂict of interest
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